Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 31 July 2024 AM
An extra $1 billion was spent subsidising medicines to treat Australians in the 2023/24 financial year, as the Federal Government funded new cancer treatments and GLP-1 sales took off.
According to information provided by Services Australia, pre-rebate reimbursements from the R/PBS totaled $17.81 billion in the financial year ending June 2024 - a 6.16 per cent increase on the $16.77 billion earned the previous financial year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.